The Role of Herceptin in Early Breast Cancer
Author Information
Author(s): Subramanian Ashok, Mokbel Kefah
Hypothesis
Does HER2 overexpression predict adjuvant tamoxifen failure in patients with breast cancer?
Conclusion
Herceptin is a significant treatment for breast cancer, particularly for patients with HER2 overexpression.
Supporting Evidence
- Herceptin has shown a recurrence risk reduction of approximately 50% in clinical trials.
- Patients with HER2 overexpression have a higher risk of tamoxifen resistance.
- The combination of Herceptin and Tamoxifen has been shown to be more effective in certain breast cancer cell lines.
Takeaway
Herceptin helps treat some breast cancer patients by targeting a specific problem in their cancer cells.
Methodology
The review discusses various clinical trials and studies regarding Herceptin's effectiveness in treating early breast cancer.
Potential Biases
Conflicting results regarding the best antibody to use in determining HER2 status may introduce bias.
Limitations
The follow-up duration of the trials is relatively short, and the optimal duration of Herceptin treatment is still debated.
Participant Demographics
The study involved a diverse group of breast cancer patients, including those with different HER2 and hormone receptor statuses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website